Restorgenex Corporation (RESX) 1.5000 $RESX Diffusion

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Restorgenex Corporation (RESX) 1.5000 $RESX

Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
GlobeNewswire - Mon Jan 25, 6:30AM CST
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Markets under the trading symbol "DFFN" (OTCQXFFN). The previous trading symbol was "RESX" (OTCQX:RESX).

Diffusion Pharmaceuticals Announces Presentation at Biotech Showcase 2016
GlobeNewswire - Fri Jan 08, 3:08PM CST
Diffusion Pharmaceuticals, LLC (OTCQX:RESX), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 - 13, 2016 in San Francisco.

Diffusion Pharmaceuticals Completes Merger With RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company
GlobeNewswire - Fri Jan 08, 3:05PM CST
Diffusion Pharmaceuticals LLC, a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the successful completion of its merger with RestorGenex Corporation (OTCQX:RESX). The combined company is changing its name to Diffusion Pharmaceuticals Inc.

The Life Sciences Report Announces the RestorGenex and Diffusion Pharmaceuticals Merger
Marketwired - Mon Dec 28, 8:00AM CST
The merger of RestorGenex Corp. (OTCQX: RESX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia.

Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird" in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
ATHX: 2.22 (+0.05), IMUC: 0.23 (unch), BCLI: 2.47 (+0.06)

RestorGenex Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:15PM CST
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and financial results for the nine months ended September 30, 2015.

SeeThruEquity's Ajay Tandon and Jay Albany Interviewed by The Life Sciences Report
Marketwired - Thu Oct 29, 12:17PM CDT
SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.
AEMD: 6.04 (+0.34)

RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.

RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.

RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.

RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.

SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.

OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.

RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.

RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".

RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.

Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.

RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.

RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.

RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 489

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CommBank Yello Builds a Wider Moat Around Customers

Updated Category News Views 23

Nine million customers is not a pilot program; it is a crowded stadium, and CommBank has decided to hand everyone a reason to stay in their seats. Commonwealth Bank's expanded CommBank Yello program now lets eligible customers earn points across home loans, term deposits, cards and insurance, then redeem with well-known brands. That is a serious attempt to make a bank...

Continue Reading

Top 5 Most Recently Viewed Articles

Aitech Honored for Its Breakthrough in Rugged AI Technology

Updated Category News Views 382

Aitech Secures 2025 Artificial Intelligence Excellence Award Aitech, renowned for its rugged embedded systems tailored for military, aerospace, and space applications, has recently been distinguished as a winner in the 2025 Artificial Intelligence Excellence Awards organized by the Business Intelligence Group. This accolade celebrates the innovative strides in AI and...

Continue Reading
National Hydropower Association Emphasizes Hydropower's Importance

Updated Category News Views 129

National Hydropower Association Celebrates Hydropower Day The National Hydropower Association (NHA), the foremost trade association for the water power industry in the U.S., is excited to celebrate National Hydropower Day. This annual event pays tribute to the water power sector and the dedicated American workers who contribute to this essential renewable resource. The...

Continue Reading
Changing Perspectives: German Parents Embrace Cannabis Cultivation

Updated Category News Views 269

Changing Perspectives on Cannabis in Germany In Germany, the landscape of cannabis use has transformed remarkably in the past year. With the legislation on cannabis legalization now in effect, the cultural and social dynamics are evolving. Although there are mixed feelings on the topic, it's evident that younger people, particularly parents, are leaning towards supporting...

Continue Reading
Select Water Solutions Unveils 2025 Q1 Earnings Event Details

Updated Category News Views 257

Select Water Solutions Announces 2025 First Quarter Earnings Select Water Solutions, Inc. (NYSE: WTTR) is gearing up for the announcement of its financial performance for the first quarter of 2025. The company has confirmed the release date of these results, which is set to take place after the market closes on an upcoming Tuesday. This is an exciting time for investors...

Continue Reading
Colabor Group's Strategic Moves Shape Future Financial Outlook

Updated Category News Views 183

Colabor Group's Financial Performance Overview Colabor Group Inc. (TSX: GCL) reveals its financial results for the fourth quarter and fiscal year, providing insights into its ongoing market performance. Fourth Quarter Highlights In the fourth quarter, Colabor Group demonstrated resilience with a sales increase of 3.2%, reaching $202.6 million. Comparatively, sales were at...

Continue Reading